---
title: "Q-Line Biotech Ltd (QLINE) — Share Price, Financials & Analysis"
symbol: "QLINE"
company: "Q-Line Biotech Ltd"
canonical: "https://tapetide.com/stocks/QLINE"
isin: "INE1G2W01011"
nse_symbol: "QLINE"
sector: "Healthcare"
industry: "Medical Equipment"
market_cap_cr: 1670.3
generated_at: "2026-09-13T18:57:12.134Z"
---

# Q-Line Biotech Ltd (QLINE)

Canonical page: https://tapetide.com/stocks/QLINE

## Company

- **NSE Symbol:** QLINE
- **ISIN:** INE1G2W01011
- **Sector:** Healthcare
- **Industry:** Medical Equipment
- **Macro Sector:** Healthcare
- **Listed Since:** 2026-05-29
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** qlinebiotech.com

## About

Incorporated in 2010, Q-Line Biotech Ltd. 
is engaged in the business of developing, manufacturing and marketing a diverse 
range of reagents.[1]

## Latest Price

- **Price:** ₹726.2
- **Change:** +11.25 (+1.57%)
- **Open:** ₹704.95
- **Day High:** ₹730
- **Day Low:** ₹694.95
- **Previous Close:** ₹714.95
- **Volume:** 66000
- **As Of:** 2026-09-11T10:01:37+00:00

## Key Fundamentals

Observed at 2026-09-11T04:54:11.883750Z.

- **Market Cap:** ₹1670.3 Cr
- **Classification:** SME
- **P/E (reported):** 29.9
- **Book Value:** ₹209.24
- **Price to Book:** 3.42
- **Dividend Yield:** 0%
- **ROE:** 12.91%
- **ROCE:** 21.31%
- **Debt to Equity:** 0.91
- **Revenue (yearly):** ₹341.74 Cr
- **Net Income:** ₹55.64 Cr
- **EBITDA:** ₹97.06 Cr
- **52-Week High:** ₹720
- **52-Week Low:** ₹343
- **RSI (14):** 79.54

## Key Insights

### Strengths

- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%

### Weaknesses

- Debtor days have increased from 92.7 to 134 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| ebitda margin growth | 10.16% | 8.34% | 41.33% |
| net income growth | -2.3% | 127.1% | 21% |
| revenue growth | 23.22% | 5.93% | 23% |
| roce | — | 15% | -9.13% |
| roe | — | -3.44% | 14.36% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21 | 31 |
| Other Income | -11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| Profit before tax | 22 | 46 |
| Tax % | 71 | 26 |
| Net Profit | 9 | 34 |
| EPS in Rs | 56.13 | 21.14 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 183 | 203 | 314 | 342 |
| Expenses | 149 | 165 | 239 | 244 |
| Operating Profit | 34 | 38 | 75 | 98 |
| OPM % | 18 | 19 | 24 | 29 |
| Other Income | 2 | 3 | -8 | 5 |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| Profit before tax | 30 | 31 | 44 | 73 |
| Tax % | 28 | 29 | 45 | 23 |
| Net Profit | 32 | 34 | 28 | 56 |
| EPS in Rs | 203.81 | 218.67 | 178.6 | 34.24 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74 | 97 | 166 | 225 |
| Other Liabilities | 51 | 81 | 99 | 87 |
| Total Liabilities | 252 | 339 | 455 | 559 |
| Fixed Assets | 23 | 60 | 92 | 145 |
| CWIP | 12 | 19 | 63 | 15 |
| Investments | 16 | 29 | 0 | 17 |
| Other Assets | 201 | 232 | 301 | 381 |
| Total Assets | 252 | 339 | 455 | 559 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 25 | -24 | -1 | 16 |
| Cash from Investing Activity | -26 | -45 | -59 | -29 |
| Cash from Financing Activity | 26 | 17 | 53 | 42 |
| Net Cash Flow | 25 | -52 | -7 | 29 |
| Free Cash Flow | -5 | -72 | -58 | -19 |
| CFO/OP | 111 | -39 | 7 | 43 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 226 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | -44 | 51 | 45 | 62 |
| ROCE % | — | 16 | 25 | 22 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 |
| --- | --- |
| Promoters | 96.77% |
| FIIs | 0% |
| DIIs | 0% |
| Government | 0% |
| Public | 0% |
| Others | 3.23% |
| No. of Shareholders | 0 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 644.65 | Buy |
| EMA (10) | 650.33 | Buy |
| SMA (20) | 589.56 | Buy |
| EMA (20) | 611.57 | Buy |
| SMA (50) | 554.61 | Buy |
| EMA (50) | 569.25 | Buy |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 80.54 | Sell |
| MACD (12,26,9) | 42.31 | Buy |
| Stochastic (14,3,3) | 92.91 | Sell |
| ADX (14) | 28.29 | Buy |
| Williams %R (14) | -1.79 | Sell |
| ATR (14) | 33.47 | High Volatility |
| ROC (12) | 35.25 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 59.66 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 Sep - Q-Line Biotech corrects AGM number typo: 37th to 16th in September 7 intimation subjects. | [Updates 8 Sep - Q-Line Biotech corrects AGM number typo: 37th to 16th in September 7 intimation subjects.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_08092026172556_Clarification_Letter.pdf) |
| 8 Sep - Newspaper notice published for 16th AGM on September 30, 2026, at Lucknow venue in physical mode. | [Copy of Newspaper Publication 8 Sep - Newspaper notice published for 16th AGM on September 30, 2026, at Lucknow venue in physical mode.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_08092026162003_Advertisement_.pdf) |
| 7 Sep - Q-Line Biotech submitted FY2025-26 annual report and scheduled AGM on 30 September 2026. | [General Updates 7 Sep - Q-Line Biotech submitted FY2025-26 annual report and scheduled AGM on 30 September 2026.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_07092026180924_Annual_Report.pdf) |
| 7 Sep - Q-Line Biotech filed FY2025-26 annual report and AGM notice for 30 September 2026. | [Updates 7 Sep - Q-Line Biotech filed FY2025-26 annual report and AGM notice for 30 September 2026.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_07092026181405_Annual_Report.pdf) |
| 7 Sep - Q-Line Biotech AGM scheduled for 30 September 2026; annual report, director reappointments, and cost auditor ratification. | [Shareholders meeting 7 Sep - Q-Line Biotech AGM scheduled for 30 September 2026; annual report, director reappointments, and cost auditor ratification.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_07092026173746_Notice.pdf) |
| 5 Sep - Board approved FY26 report, 16th AGM on Sept 30, 2026, and reappointed directors and cost auditor. | [Outcome of Board Meeting 5 Sep - Board approved FY26 report, 16th AGM on Sept 30, 2026, and reappointed directors and cost auditor.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_05092026181404_QLine_Biotech_Outcome_of_Board_Meeting.pdf) |
| 30 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet proposed to be held on 03rd July 2026 at 03:30 PM | [Analysts/Institutional Investor Meet/Con. Call Updates 30 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet proposed to be held on 03rd July 2026 at 03:30 PM](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_30062026200001_Group_of_Investor_Meeting.pdf) |
| 30 Jun - Q-Line Biotech held FY26 earnings call; revenue rose 9% to ₹341.7 crore, PAT to ₹55.7 crore. | [Analysts/Institutional Investor Meet/Con. Call Updates 30 Jun - Q-Line Biotech held FY26 earnings call; revenue rose 9% to ₹341.7 crore, PAT to ₹55.7 crore.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_30062026214959_Q-Line-H2FY26_Earnings_Call_Transcript_.pdf) |
| 27 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet of Group of Investors | [Analysts/Institutional Investor Meet/Con. Call Updates 27 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet of Group of Investors](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_27062026164235_Group_of_Investors_Meeting.pdf) |
| 27 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialized share certificates. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 27 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialized share certificates.](https://nsearchives.nseindia.com/corporate/QLINEBIOTECH_27072026180301_QLine_Biotech_Reg_74.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31716_QLINE_2025_2026_A_26003711_07092026174445.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:57:12.134Z.